{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2012"],"condition":["Cancer colorectal metastásico.","Metastatic Colorectal Cancer","Colorectal cancer metastatic","Colorectal cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Cancer","Cancer Colorectal Metastásico.","Colorectal Cancer Metastatic","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2128557"],"location":["Spain"],"study_start_month":["7"],"keyword":["Irinotecan","acido Folínico","FOLFOXIRI","5-Fluorouracilo","Circulating tumor cell","FOLFOX","oxaliplatino","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells","description":"The purpose of the study is to evaluate FOLFOX + bevacizumab versus FOLFOXIRI + bevacizumab as first line treatment of patients with metastatic colorectal cancer not previously treated and with three or more circulating tumoral cells.","dates":{"creation":"2012-07-15"},"accession":"2128557","cross_references":{"ClinicalTrials___gov":["NCT01640405"],"EU Clinical Trials Register":["2012-000846-37"]}}